NCT07347444

Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma

A Prospective, Single-arm, Multicenter, Phase II Clinical Study of Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single-arm, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of iparomlimab and tuvoraleimab, in combination with bevacizumab, albumin-bound paclitaxel, and carboplatin as first- or second-line treatment in patients with acral and mucosal melanoma.

Conditions

• Acral Melanoma
• Mucosal Melanoma

Interventions

Type	Name	Description
DRUG	Iparomlimab and Tuvoraleimab injection+Bev+nab-PC	Iparomlimab and Tuvoraleimab injection: 5mg/kg, D1,Q3W; Bevacizumab: 7.5 mg/kg, D1, Q3W; Albumin-bound paclitaxel: 125mg/m2, D1,8, Q3W; Carboplatin: AUC=2, D1,8, Q3W.

Timeline

• Start date: 2026-02-01
• Primary completion: 2028-12-01
• Completion: 2028-12-01
• First posted: 2026-01-16
• Last updated: 2026-01-16

Locations

1 site across 1 country: China